dexmethylphenidate

Adjunctive therapy • Brands: FOCALIN, FOCALIN XR

Last reviewed: 2026-02-20

General information

Class: Adjunctive therapy
Common US brands: FOCALIN, FOCALIN XR
Typical dose range: Typical initiation is at a low dose with weekly titration based on benefit and tolerability; immediate-release products are commonly BID, while extended-release products are usually once daily in the morning.
Therapeutic drug monitoring not routinely recommended.
Last reviewed: 2026-02-20

Dosing & forms

Forms/strengths: Immediate-release tablets (often dosed twice daily).; Extended-release capsules (typically once daily in the morning).
Frequency: Typical initiation is at a low dose with weekly titration based on benefit and tolerability; immediate-release products are commonly BID, while extended-release products are usually once daily in the morning.
Typical range: Typical initiation is at a low dose with weekly titration based on benefit and tolerability; immediate-release products are commonly BID, while extended-release products are usually once daily in the morning.

Mechanism (brief)

CNS stimulant; d-enantiomer of methylphenidate that inhibits dopamine and norepinephrine reuptake (DAT/NET).

Metabolism & Half‑life

Metabolism: CES1 (carboxylesterase) to inactive metabolites
Half‑life: Single-dose mean 3 h

Therapeutic Drug Monitoring (TDM)

Recommended: No

View labelExact

Monitoring highlights

Baseline and periodic blood pressure and heart rate (more often during titration).
Appetite and weight/BMI, with nutrition and meal timing revisited if weight loss occurs.
Sleep onset and total sleep time; timing/formulation adjustments are often tried before adding sedatives.
Anxiety, agitation, mood elevation, or hallucinations; emergent symptoms generally prompt reassessment and discontinuation when appropriate.
Misuse/diversion risk at follow-up; safe storage counseling is commonly documented.

Sources

Focalin (dexmethylphenidate HCl) prescribing information — DailyMed (2025)
Focalin XR (dexmethylphenidate HCl extended-release) prescribing information — DailyMed (2025)
Attention deficit hyperactivity disorder (NICE guideline NG87) — NICE (2018)
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents — Pediatrics (2019)
Comparative efficacy and tolerability of medications for ADHD (systematic review and network meta-analysis) — Lancet Psychiatry (2018)

General information

Class: Adjunctive therapy

Common US brands: FOCALIN, FOCALIN XR

Typical dose range: Typical initiation is at a low dose with weekly titration based on benefit and tolerability; immediate-release products are commonly BID, while extended-release products are usually once daily in the morning.

Therapeutic drug monitoring not routinely recommended.

Last reviewed: 2026-02-20

Dosing & forms

Forms/strengths: Immediate-release tablets (often dosed twice daily).; Extended-release capsules (typically once daily in the morning).

Frequency: Typical initiation is at a low dose with weekly titration based on benefit and tolerability; immediate-release products are commonly BID, while extended-release products are usually once daily in the morning.

Typical range: Typical initiation is at a low dose with weekly titration based on benefit and tolerability; immediate-release products are commonly BID, while extended-release products are usually once daily in the morning.

Monitoring highlights

Baseline and periodic blood pressure and heart rate (more often during titration).

Appetite and weight/BMI, with nutrition and meal timing revisited if weight loss occurs.

Sleep onset and total sleep time; timing/formulation adjustments are often tried before adding sedatives.

Anxiety, agitation, mood elevation, or hallucinations; emergent symptoms generally prompt reassessment and discontinuation when appropriate.

Misuse/diversion risk at follow-up; safe storage counseling is commonly documented.